{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:03:21Z","timestamp":1793754201392,"version":"4.6.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024838","name":"Samsung Medical Center, Sungkyunkwan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024838","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtho.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:14:35Z","timestamp":1746796475000},"page":"1279-1288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial"],"prefix":"10.1016","volume":"20","author":[{"given":"Sehhoon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Kyung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Joo","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jii Bum","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-2195","authenticated-orcid":false,"given":"Min Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.05.006_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103996","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer","volume":"9","author":"Lee","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2025.05.006_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.23.02744","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jtho.2025.05.006_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102080","article-title":"Uncommon EGFR mutations in non-small-cell lung cancer: a systematic literature review of prevalence and clinical outcomes","volume":"76","author":"John","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jtho.2025.05.006_bib5","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1158\/1078-0432.CCR-23-4035","article-title":"From rarity to reality: osimertinib\u2019s promising horizon in treating uncommon EGFR mutations in non-small cell lung cancer","volume":"30","author":"Fukuda","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.05.006_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","article-title":"First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN Phase 2 nonrandomized clinical trial","volume":"10","author":"Okuma","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-a systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib8","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib9","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.05.006_bib10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, Phase II trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib12","article-title":"EGFR Exon 18 mutations in advanced non-small cell lung cancer: a real-world study on diverse treatment patterns and clinical outcomes","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib13","article-title":"A lung adenocarcinoma patient with a rare EGFR E709_T710delinsD mutation showed a good response to afatinib treatment: a case report and literature review","volume":"11","author":"Wei","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib15","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1200\/JCO.2024.42.16_suppl.8516","article-title":"Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): results from CHRYSALIS-2","volume":"42","author":"Cho","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.05.006_bib16","article-title":"The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC","volume":"6","author":"Oh","year":"2025","journal-title":"Cell Rep Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425007130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425007130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:31:43Z","timestamp":1772483503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425007130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1556086425007130"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.05.006","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}